Xu Weiguo, Wu Junhua, Feng Yong, Zhu Jing, Cui Rong
Department of Respiratory, Mianyang Central Hospital of Sichuan Province, Mianyang, Sichuan, China.
Department of Traditional Chinese Medicine, Mianyang Central Hospital of Sichuan Province, Mianyang, Sichuan, China.
Pak J Pharm Sci. 2019 Sep;32(5(Special)):2489-2493.
To observe the clinical efficacy of aerosol inhalation of ipratropium bromide and terbutaline on the patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). A total of 136 COPD patients with acute exacerbation were divided into the ipratropium bromide group (n=69) and the terbutaline group (n=67). Patients in the ipratropium bromide group were required to take ipratropium bromide, while those in the terbutaline group took terbutaline for 3 days. Then, changes in symptoms, vital signs, blood-gas indicators and pulmonary functions were compared and analyzed between two groups. In ipratropium bromide group, patients with amelioration in vital signs and symptoms, especially for the symptom of coughing (P<0.01), were more than those in the terbutaline group, with statistically significant difference (P<0.05). In addition, following medication, analysis showed that the improvement in the blood-gas indicators and pulmonary functions in the ipratropium bromide was excellent in comparison with the terbutaline group, especially the improvement in the pulmonary ventilation function (P<0.01). Comparison over the incidence rates of adverse events in the ipratropium bromide group and terbutaline group showed an evident difference (P<0.05). For treatment of patients with acute exacerbation of COPD, aerosol inhalation of ipratropium bromide is a safe but effective method.
观察异丙托溴铵与特布他林雾化吸入治疗慢性阻塞性肺疾病（COPD）急性加重期患者的临床疗效。将136例COPD急性加重期患者分为异丙托溴铵组（n = 69）和特布他林组（n = 67）。异丙托溴铵组患者给予异丙托溴铵，特布他林组患者给予特布他林，疗程均为3天。然后，比较分析两组患者的症状、生命体征、血气指标及肺功能变化。结果显示，异丙托溴铵组生命体征及症状改善患者多于特布他林组，尤其咳嗽症状改善明显（P < 0.01），差异有统计学意义（P < 0.05）。此外，用药后分析表明，异丙托溴铵组血气指标及肺功能改善情况优于特布他林组，尤其是肺通气功能改善明显（P < 0.01）。比较异丙托溴铵组与特布他林组不良事件发生率，差异有统计学意义（P < 0.05）。对于COPD急性加重期患者的治疗，雾化吸入异丙托溴铵是一种安全有效的方法。
